Relief may be brief, and some choices may not help

Cortisone usually helps early, then the relief fades

Cortisone has helped most during the first weeks in research. By 26 weeks, researchers couldn’t show that it was still easing pain. That doesn’t mean nobody felt better. It means lasting relief wasn’t clear for the group.

A short spell of relief may still help you walk or exercise. It won’t meet your needs if you expect a long change. So here’s the question to ask: how long did people feel better? Then decide whether that length of time matters to you.

Gel and blood-based care may help, but the results don’t agree

When many gel studies were put together, the average change was too small for most patients to feel. Some people still report relief. The research can’t tell us your chance of being one of them. Cost matters when the expected gain is small.

Some groups of studies found more relief with platelet-rich plasma (PRP). Yet in one large trial, PRP did no better after 12 months than salt water with no medicine. QC Kinetix offers PRP as one of its natural pain treatments. It starts with your blood, which the clinic spins until a small amount holds more platelets, then places inside your knee with a needle.

No study can promise what your knee will feel

A study tells us what happened to a group, not what will happen to you. Your health and past results may be different. Even good research can’t name your result before treatment. Honest care admits that doubt.

Tell the person examining you what you need the knee to do. Ask when you’d expect to notice relief and when you’d stop waiting for it. Get the full cost before deciding too. Those answers are more useful than a broad claim that something works.

Sources

1. The 2015 Cochrane review of 27 trials (1,767 participants) found intra-articular corticosteroid better than sham for knee OA pain (SMD -0.40, 95% CI -0.58 to -0.22; NNTB 8), but the benefit decayed with time: moderate at 1-2 weeks, small at 13 weeks, and no evidence of any effect at 26 weeks. All outcomes were graded LOW quality.

   Jüni P, et al. — Intra-articular corticosteroid for knee osteoarthritis.. Cochrane Database Syst Rev, 2015. DOI: 10.1002/14651858.CD005328.pub3.

2. In a 2-year double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, 40 mg intra-articular triamcinolone every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with no significant difference in knee pain.

   McAlindon TE, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

3. A 2022 BMJ systematic review and meta-analysis of 169 trials (21,163 participants) found viscosupplementation produced only a small pain reduction versus placebo (SMD -0.08, 95% CI -0.15 to -0.02; about -2.0 mm on a 100 mm VAS), below the minimal clinically important difference, and trial sequential analysis indicated conclusive evidence of clinical equivalence with placebo since 2009.

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

4. The RESTORE randomized trial (288 participants, leukocyte-poor PRP, 3 weekly injections) found no significant difference from saline placebo at 12 months in knee pain (-2.1 vs -1.8 points; difference -0.4, 95% CI -0.9 to 0.2) or in medial tibial cartilage volume (-1.4% vs -1.2%), with 29 of 31 secondary outcomes also showing no between-group difference.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

5. The 2025 Cochrane living review of stem cell injections for knee OA (25 trials, 1,341 participants) found stem cell injection MAY slightly improve pain and function up to six months versus placebo (pain 1.2 points better on a 0-10 scale; function 14.2 points better on 0-100), but rated the evidence LOW certainty for both, downgraded for indirectness and suspected publication bias, with up to three larger RCTs withdrawn before reporting results.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database Syst Rev, 2025. DOI: 10.1002/14651858.CD013342.pub2.

6. FDA's HCT/P guidance sets out the minimal-manipulation and homologous-use criteria that decide whether a human cell or tissue product is regulated solely under 21 CFR Part 1271 (section 361) or requires a biologics licence; cell-based orthopaedic injections that fall outside those criteria are unapproved drugs and biological products, and no cell-based product is FDA-approved to treat osteoarthritis.

   U.S. Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and FDA Staff. U.S. Food and Drug Administration, 2020.

7. The AAOS third-edition non-arthroplasty knee OA guideline (2022) issues 29 recommendations across non-pharmacologic and pharmacologic care, and its work group explicitly flagged the need for better research on intra-articular corticosteroid, hyaluronic acid and platelet-rich plasma.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. J Am Acad Orthop Surg, 2022. DOI: 10.5435/JAAOS-D-21-01233.